Batoclimab  (Synonyms: 巴托利单抗; RVT-1401; HBM9161; IMVT-1401)

Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

FcRn

2217  [NCBI]

P55899

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

143.43 kDa

2187430-05-1

液体

Colorless to light yellow

巴托利单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda2

• 
  Immobilized FCRN-B2M Protein, Human (HEK293, His, HY-P70601) can bind Batoclimab. The EC₅₀ for this effect is 97.79 ng/mL.

• [1]. Yan C, et, al. Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study. Neurol Ther. 2022 Apr 12.  [Content Brief]

  [2]. Kahaly GJ, et al. Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease. J Clin Endocrinol Metab. 2023 Nov 17;108(12):3122-3134.  [Content Brief]